Key result
Renal denervation reviews mechanisms, trial setbacks, and emerging technologies for resistant hypertension.
Why the study?
Does renal denervation lower blood pressure in patients with resistant hypertension?
Does renal denervation lower blood pressure in patients with resistant hypertension?
Despite early setbacks in clinical trials, novel techniques to achieve more complete renal sympathetic denervation may still offer a viable therapeutic option for patients with resistant hypertension.
Renal denervation should not yet change practice after negative SYMPLICITY HTN-3; leaves open whether refined complete-denervation technologies will succeed in resistant hypertension.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Raman et al. (2015) conducted a review in Resistant hypertension. Renal denervation was evaluated. This review discusses the mechanisms, clinical trial outcomes including the negative SYMPLICITY HTN-3 trial, and future technologies for achieving complete renal denervation in resistant hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: